Nicolazzo et al. evaluated the expression of PD-L1 in CTCs from NSCLC patients at the baseline, and at 3 and 6 months after starting Nivolumab treatment, using the EpCAM-based CellSearch enumeration platform. Here, CD274 is linked to non-small cell lung carcinoma.